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Background: High throughput technologies offer insight into disease processes and heightens opportunities for
improved diagnostics. Using transcriptomic analyses, we aimed to discover and to evaluate the clinical validity of a
combination of reliable and functionally important biomarkers of serious bacterial infection (SBI).
Methods: We identified three previously reported biomarkers of infection (neutrophil gelatinase-associated lipocalin
(NGAL), granulysin and resistin) and measured gene expression using quantitative real-time PCR. Protein products
related to the three transcripts were measured by immunoassays.
Results: Relative gene expression values of NGAL and resistin were significantly increased, and expression of
granulysin significantly decreased in cases compared to controls. Plasma concentrations of NGAL and resistin were
significantly increased in children with confirmed SBI compared to children with no detectable bacterial infection
(NBI), and to controls (287 versus 128 versus 62 ng/ml and 195 versus 90 versus 18 ng/ml, respectively, p< 0.05).
Plasma protein concentrations of NGAL and resistin were significantly increased in non-survivors compared to
survivors (306 versus 211 and 214 versus 150 ng/ml, p = 0.02). The respective areas under the curve (AUC) for NGAL,
resistin and procalcitonin in predicting SBI were 0.79, 0.80 and 0.86, whilst a combination of NGAL, resistin and
procalcitonin achieved an AUC of 0.90.
Conclusions: We have demonstrated a unique combination of diagnostic biomarkers of SBI using transcriptomics,
and demonstrated translational concordance with the corresponding protein. The addition of NGAL and resistin
protein measurement to procalcitonin significantly improved the diagnosis of SBI.
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Serious bacterial infection (SBI) remains an important con-
tributor to mortality and morbidity in children, particularly
in resource-poor countries. Child deaths attributable to
invasive Streptococcus pneumoniae and Haemophilus
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reproduction in any medium, provided the orcollectively attributable to HIV, tuberculosis and malaria
[1,2]. The prompt recognition of SBI in children is challen-
ging clinically, especially so in the context of co-infection
with malaria and HIV [3], and is of the utmost importance
in ensuring both effective, and rational antibiotic treatment.
Diagnostic uncertainty in bacterial sepsis is compensated
by the overuse of antibiotics in self-limiting infections, lead-
ing to antibiotic resistance.
Biomarkers may be used alone or in combination to allow
classification of an individual to a unique group with
defined characteristics. Biomarkers which reflect the host
response to infection are useful adjuncts to good clinicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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confirming SBI. Advances in transcriptomics and proteo-
mics have provided basis for biomarker panels unravelled
from these technologies, that might be useful in differenti-
ating sepsis-associated inflammation from non-infectious
inflammation [4]. An improved understanding of the mech-
anism of sepsis, and the ability to identify and quantify key
mediators involved in its pathophysiology, offers the pro-
spect of reliable diagnostic and prognostic tools. Transcrip-
tion profiling has been used in other diseases to identify
candidate biomarkers [5-7].
Over 170 biomarkers have been related to sepsis, but
relatively few have been evaluated as diagnostic markers. A
comprehensive review on sepsis biomarkers, concluded that
it is unlikely that a single ideal biomarker will ever be
found, and that a combination of biomarkers may be more
effective [8]. Many of the markers so far investigated are
costly and time-consuming to measure. Studies of panels of
biomarkers have yielded encouraging results, but none of
them have potential to be measured as an affordable point-
of- care (POC) test.
The performance of biomarkers is traditionally assessed
using receiver operator characteristic (ROC) curves. ROC
curves evaluate the discrimination of a test (or combin-
ation of tests), but may be insensitive to the addition of a
new biomarker, especially if a good biomarker is already
included in the model. Net reclassification improvement
(NRI) quantifies improvement in the model as a result of
adding one or more new biomarkers. This approach has
been used in cardiovascular disease [9] and acute lung in-
jury [10] to improve the accuracy of risk prediction.
Resistin is an adipokine first related to insulin resistance
in mice [11]. In humans, resistin expression occurs pre-
dominantly in macrophages, monocytes and neutrophils
[12,13]. Circulating resistin levels peak 8-16 h after the ad-
ministration of LPS in healthy subjects, mediated by pro-
inflammatory cytokines and NF-κB [14]. Resistin is signifi-
cantly elevated in intensive care patients with sepsis [15],
and levels correlate with severity of disease [16,17].
Neutrophil gelatinase-associated lipocalin (NGAL) – or
lipocalin 2 –has a role in innate immunity through its
ability to bind siderophores, required by many bacterial
pathogens to scavenge iron from the host [18]. Like resis-
tin, it is highly upregulated by inflammatory stimuli via
NF-κB [19]. NGAL is more significantly elevated in sepsis
than in the systemic inflammatory response syndrome
(SIRS) [20-22]. In a large study of adult patients with sus-
pected sepsis presenting to an emergency department, the
optimal 3-marker panel was NGAL, protein C, and inter-
leukin-1 receptor antagonist. The area under the curve for
the accuracy of the sepsis score derived from these three
biomarkers was 0.80 for severe sepsis, 0.77 for septic
shock, and 0.79 for death [23].Granulysin is an antimicrobial protein co-localised with
perforin in the granules of cytotoxic T lymphocytes (CTLs)
and natural killer (NK) cells. It has a direct cytotoxic effect
on numerous extracellular pathogens, and is postulated to
kill intracellular organisms such asMycobacterium tubercu-
losis in conjunction with perforin [24]. Granulysin levels
correlate inversely with disease activity in M. tuberculosis
and normalise with treatment [25]. Granulysin is transiently
elevated in acute viral infections, and has been suggested as
a marker of host cellular immunity [26].
We aimed to identify differentially regulated biomarker
transcripts in children with SBI using microarray technol-
ogy. Three previously identified biomarkers were validated
by quantitative real-time PCR in an independent prospect-
ive cohort. In order to determine the diagnostic utility of
the biomarkers to predict SBI, we measured the proteins
of the differentially regulated biomarker genes in plasma
samples, to determine if they could reliably predict SBI, or
outcome from SBI.Results and discussion
Results
Of the 377 children included in the study, 282 (74.8%) pre-
sented with meningitis and 95 (25.2%) presented with
pneumonia. The baseline characteristics are summarised in
Table 1. There were no significant differences in clinical
characteristics (duration of symptoms, previous antibiotics,
nutritional status) between children with serious bacterial
infection (SBI) and children with signs of severe sepsis but
no detectable bacterial infection (NBI), but as expected, the
proportion of children presenting with signs of meningitis
was significantly higher in the SBI group. The numbers of
patients in whom we measured NGAL, resistin, granulysin
and procalcitonin are shown in Figure 1, according to
STARD guidelines [27].Relative gene expression
In the biomarker discovery set using microarray, we studied
12 children with serious bacterial infection (HIV-infected
non-survivor n=3, HIV-infected survivor n=3, HIV-unin-
fected non-survivor n=3, HIV-uninfected survivor n=3),
and the control group (n=3). We identified three genes
previously reported to be biomarkers of bacterial infection:
resistin (RETN), neutrophil gelatinase associated lipocalin
(LCN2) and granulysin (GNLY). The following fold changes
were observed in controls compared to cases: Resistin
−5.88 (p=0.06), NGAL −4.19, (p=0.002) and granulysin
3.14 (p=0.002). These three genes were chosen because a)
there was a priori evidence in the literature that they could
be markers of infection, b) they had the highest fold
changes (>3, <–3), and c) they were all available as com-
mercial ELISAs for measurement of protein in plasma
samples.
Table 1 Characteristics of children with confirmed serious bacterial infection (SBI), those with no detectable bacterial
infection (NBI) and controls
SBI (n = 280) NBI (n = 97) Controls (n = 15) p value
Age (years), median(IQR) 2.0 (0.6 – 6.9) 2.5 (1.0 – 5.7) 10.0 (6.0-13.0) <0.0005
Males 154 (55%) 61 (63%) 13/21 (62%) <0.0005
Duration of symptoms (days), median(IQR) 3 (2 – 5) 3 (2 – 5) NR 0.76
Previous antibiotics (%) 123 (44%) 37 (38%) NR 0.32
Meningitis (%) 235 (84%) 47 (49%) NR <0.0005
Mortality (%) 68 (24%) 15 (15%) NR 0.02
HIV-infected (%) 145 (52%) 45 (47%) 0 (0%) <0.0005
Height for age Z score<− 3 (%) 42/272 (15%) 16/91 (18%) ND 0.63
Weight for height Z score<− 3 (%) 37/218 (17%) 11/82 (13%) ND 0.45
White cell count (WCC) x109/l median(IQR) 12.6 (7.8 – 20.0) 13.8 (10.0 – 20.4) ND 0.09
Neutrophil count x109/l median(IQR) 10.6 (4.6 – 16.3) 8.9 (5.5 – 15.5) ND 0.78
Numeric values are median and interquartile range (IQR). (ND=not done, NR= not relevant in a healthy control). Statistical comparison is between three groups,
SBI, NBI and controls, using the Kruskal =Wallis test.
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with serious bacterial infection. Children from the micro-
array discovery set were excluded. Relative gene expression
of resistin and NGAL were significantly increased in cases
compared to controls (p< 0.001), and relative gene expres-
sion of granulysin was decreased in cases compared to con-
trols. Relative gene expression of NGAL (median 41.2 v
17.7, p =0.012) granulysin (0.1 v 0.07, p= 0.04) and resistin
(13.7 v 11.0, p =0.26), was increased in non-survivors com-
pared to survivors (Figure 2).
Plasma concentrations of NGAL, granulysin and resistin in
NBI, SBI and controls
After adjusting for HIV status, plasma concentrations of
NGAL and resistin were significantly increased in chil-
dren with SBI compared to NBI, compared to controls
(287 v 128 v 62 ng/ml and 195 v 90 v 18 ng/ml,Children with pneumonia or 
n=377 
Index tests:                            
NGAL/Granulysin/ Resistin/ 
n=219/261/181/330 









Figure 1 Flow diagram showing the number of patients undergoing
numbers of patients that had each measurement of are shown, according
biomarkers in the following order, procalcitonin, granulysin, NGAL, resistin,
tested across all four assays.p< 0.05). Plasma concentrations of granulysin were not
significantly different between the groups (Figure 3).
Plasma concentrations of NGAL, granulysin and resistin in
survivors and non-survivors
After adjusting for HIV status, plasma concentrations of
NGAL and resistin were significantly increased in non-
survivors compared to survivors (306 v 211 ng/ml and
214 v 150 ng/ml, p = 0.02). Plasma concentrations of
granulysin were not significantly different between the
groups (Figure 3).
Performance of NGAL, granulysin and resistin in
predicting SBI
The performance characteristics (sensitivity, specificity,
positive and negative predictive values, and positive and
negative likelihood ratios) of NGAL and resistin asmeningitis         











index tests and the number of patients with SBI and NBI. The
to STARD guidelines [27]. All available samples were tested for all four
as long as there was remaining sample. A total of 181 samples were
p=0.012 p=0.04 NS
Figure 2 Bar chart showing relative NGAL, granulysin and resistin expression in survivors and non-survivors. A total of 176 samples were
analysed using RT PCR. The ++ Ct method was used to calculate normalised data [28]. There was over-expression of NGAL and resistin and
under-expression of granulysin in cases compared to controls (data not shown). Relative gene expression of NGAL granulysin and resistin were
increased in non-survivors compared to survivors Error bars =mean+/−2SE NS = not significant.
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calcitonin are shown in Table 2. The areas under the
curve (AUCs) for NGAL, granulysin and resistin in pre-
dicting SBI were NGAL 0.79 (95% CI 0.73-0.85), granu-
lysin 0.56 (95% CI 0.48-0.63) and resistin 0.80 (95% CI
0.72-0.88). Procalcitonin, a previously evaluated bio-
marker in this cohort [29], had an AUC of 0.86 (0.79-
0.92). The ROC curves of the four biomarkers and the
combination of procalcitonin, resistin and NGAL are





Figure 3 Bar chart showing NGAL, granulysin and resistin concentrati
non-survivors. A total of 181 samples were tested across all 4 assays. Plasm
children with SBI compared to NBI, compared to controls. Plasma concentr
survivors compared to survivors. Error bars =mean+/−2SE NS= not significaAdditive value of the biomarkers using net reclassification
index
The addition of the biomarkers resistin and NGAL to the
currently used biomarker, procalcitonin alone, significantly
improved prediction of SBI. Granulysin was dropped from
the model because of its poor performance as a single
biomarker.
The NRI for the new prediction models are shown in
Table 3. Including resistin or NGAL or both resistin and




ons in a) controls, NBI and SBI and b) in survivors and
a concentrations of NGAL and resistin were significantly increased in
ations of NGAL and resistin were significantly increased in non-
nt, *** = p< 0.0005, * = p< 0.05.



















































PPV=positive predictive value, NPV = negative predictive value, LR += likelihood ratio for a positive result, LR- = likelihood ratio for a negative result.
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ance. In addition, the incorporation of resistin in the
current prediction model results in a 4% loss of sensitivity
(non-significant), but a (significant) 54% improvement in
specificity. The inclusion of NGAL in the current model
results in a 1% gain in sensitivity and a (significant) 56%
gain in specificity. The inclusion of both resistin and NGAL
in the current model results in a 14% gain in sensitivity and
a (significant) 67% gain in specificity.
Discussion
The diagnosis of SBI is complicated by its variable and
non-specific clinical signs and symptoms, and a failure
to recognise and promptly treat SBI results in significant
morbidity and mortality. The search for accurate bio-
markers to influence clinical practice has become para-
mount for the treatment of sepsis, but to date the search
has been disappointing [8]. We have demonstrated
concordance between transcript and protein expression
for two out of three biomarkers of SBI differentially
regulated in microarray screening, validation using
quantitative RT-PCR, and measurement of protein con-
centrations in plasma samples. The discrepancy between
RNA expression and protein concentration for granuly-
sin can be explained by a) post-translational modifica-
tion, b) reduced expression of granulysin in HIV-
infected individuals [30] (although after adjusting for
HIV the results are the same) and c) delay in granulysin
production in HIV-infected individuals due to defective
signalling in HIV [31].Table 3 Reclassification improvement in new prediction mod
New model Summary NRI
(95% CI), p-value
PCT+Resistin 0.50 (0.17, 0.83), 0.0032
PCT+NGAL 0.58 (0.29, 0.86), 0.0001
PCT+Resistin+NGAL 0.81 (0.45, 1.16), <0.0001
Event = SBI, non-event = not SBI.Our combination of three biomarkers (resistin, NGAL
and procalcitonin) demonstrates good discrimination be-
tween SBI and NBI. Adding resistin and NGAL to procal-
citonin demonstrates a net reclassification improvement
of 81%. To our knowledge, this is the first study to identify
a combination of biomarkers for the detection of SBI
using a systems biology approach, and to validate diagnos-
tic accuracy. Our data suggest possible inter-relationships
between pathways involving resistin, cytotoxic T cell activ-
ity and lipocalin-2, and a significant role for these proteins
in the host defence against bacterial infection. The exact
mechanisms require further detailed study. Resistin has
been shown to attenuate both cytokine production and T
cell activity in a dendritic cells stimulated with lipoteichoic
acid [32], and adiponectin (another adipokine) is a nega-
tive T cell regulator [33].
Transcription profiling has been used in other infec-
tious diseases to identify biosignatures of disease groups
[5-7]. The use of multiple biomarkers allows the capture
of multi-dimensional patterns and pathways, such as
those that can occur in complex biological processes like
sepsis, and is therefore more robust [34]. Our study is
now undergoing further validation in a prospective co-
hort of febrile children presenting to the emergency de-
partment of a large tertiary hospital in England.
In this study, resistin and NGAL provided good dis-
crimination of SBI from NBI (AUC: 0.80 and 0.79 re-
spectively). Individually, neither performed as well as
procalcitonin in our previous study [29]. A combination





−0.04 (−0.22, 0.12), 0.6015 0.54 (0.26, 0.82), 0.0002
0.01 (−0.15, 0.18), 0.8690 0.56 (0.32, 0.79), <0.0001
0.14 (−0.06, 0.33), 0.1700 0.67 (0.38, 0.97), <0.0001
a) PCT, granulysin, resistin NGAL singly 
b) Combined PCT, resistin and NGAL 
Figure 4 Receiver operator characteristic curves (ROC) of
markers of SBI. a) procalcitonin (PCT), granulysin, resistin and NGAL
as markers of SBI and b) combination of biomarkers (procalcitonin
(PCT), resistin and NGAL) as markers of SBI.
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interleukin-1 receptor antagonist) measured in North
American adults presenting to an emergency department
with suspected sepsis [23]. As measured by the AUC,
our combination of biomarkers resulted in a 10% im-
provement in clinical diagnostic accuracy. A more help-
ful measure however is the NRI. Clinical risk
reclassification describes how a new marker or combin-
ation of markers may add to predictive models forclinical use, and the NRI can be used to more formally
assess clinical utility. An NRI of 81% is a highly signifi-
cant improvement in reclassification for clinical
management.
Our study exemplifies translational medicine. We have
used transcriptomics to develop a better understanding
of biomarkers related to the disease process, and to
identify potent biosignatures for accurate clinical deci-
sion-making. Obstacles to the pipeline for diagnostics
have been reported at the “front end” i.e. early stages of
discovery and development, and also later, with lack of
samples for validating and testing biomarkers [35]. Our
study has overcome both these barriers, and is a major
step in addressing the pipeline problem in the diagnosis
of SBI. If our findings are confirmed prospectively, and
if the unique combination of three protein biomarkers
could be combined in POC device at low cost, then
there is great potential for such a POC device. In pri-
mary and secondary care, and in resource-poor settings,
POC testing could reduce delays in diagnosis thereby re-
ducing morbidity and mortality, and minimise unneces-
sary hospital admission and antibiotic prescribing.
Conclusions
There are currently no rapid diagnostic tests measuring
panels of biomarkers of SBI. Our study demonstrates for
the first time that a small panel derived from disease-
related biological processes, is likely to be successful.
The addition of resistin and NGAL protein measure-
ment to procalcitonin significantly improves classifica-
tion. We have identified a unique combination of
biomarkers of SBI which could help guide antibiotic
management and decisions on referral to hospital. Our
data demonstrate exciting improvements in classifica-
tion, which need to be validated prospectively in a larger
cohort.
Materials and methods
Study setting and population
Between April 2004 and October 2006, we prospectively
enrolled children who presented to the Accident and
Emergency Department and the Admissions Unit of
Queen Elizabeth Central Hospital, Blantyre, Southern
Malawi. The study setting, population and characteristics
of study patients have been described previously [29].
The primary outcome measure was bacteriological
confirmation of infection (SBI) and the secondary out-
come measure was death/survival in hospital. Afebrile
children, without malaria parasitaemia, from the same
villages as the cases, were used as controls. All controls
were HIV-uninfected. Ethical approval for this study was
granted from The College of Medicine Research Com-
mittee (COMREC), Malawi and The Liverpool School of
Tropical Medicine Research Ethics Committee. Parents
Table 4 Primer sequences and probe numbers for each assay
Gene Forward Primer Sequence Reverse Primer Sequence Universal Probe Library
GNLY AGGGTGACCTGTTGACCAAA CAGCATTGGAAACACTTCTCTG 17
LCN2 TCACCTCCGTCCTGTTTAGG AGGTAACTCGTTAATCCAGGGTAA 61
RETN TGCAGGATGAAAGCTCTCTG CATGGAGCACAGGGTCTTG 45
ACTB ATTGGCAATGAGCGGTTC GGATGCCACAGGACTCCAT 11
B2M TTCTGGCCTGGAGGCTATC TCAGGAAATTTGACTTTCCATTC 42
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 60
GNB2L1 GCTACTACCCCGCAGTTCC CAGTTTCCACATGATGATGGTC 55
HMBS AGCTATGAAGGATGGGCAAC TTGTATGCTATCTGAGCCGTCTA 25
HPRT1 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 73
PGK-1 CTGTGGCTTCTGGCATACCT CTTGCTGCTTTCAGGACCA 42
RPL13A GAGGCCCCTACCACTTCC TGTGGGGCAGCATACCTC 28
RPL32 GAAGTTCCTGGTCCACAACG GCGATCTCGGCACAGTAAG 17
SDHA AGAAGCCCTTTGAGGAGCA CGATTACGGGTCTATATTCCAGA 69
TBP GCTGGCCCATAGTGATCTTT CTTCACACGCCAAGAAACAGT 3
YWHAZ CGTTACTTGGCTGAGGTTGC TGCTTGTTGTGACTGATCGAC 9
12 endogenous transcripts (ACTB, B2M, GAPDH, GNB2L1, HMBS, HPRT1, PGK-1, RPL13A, RPL32, SDHA, TBP and YWHAZ) were screened and analysed using the
GeNORM algorithm [28].
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to enter the study.Definitions
Cases (n = 377) Children who presented with signs and
symptoms of meningitis or pneumonia, as defined previ-
ously [29].Healthy controls (n = 15) Healthy afebrile children from
the same villages as the cases, who had no malarial para-
sites on blood film. Controls were selected by parents or
guardians in the neighbourhood of the index case as part
of a larger study investigating genetic susceptibility in
IPD [36]. In a small number of children, parental con-
sent was also given to take venous samples for bio-
marker determination.Serious bacterial infection (SBI) (n = 280) Children
who presented with either bacterial meningitis or bacter-
ial pneumonia, in whom a bacterial pathogen was identi-
fied by culture, polysaccharide antigen test or PCR
(Streptococcus pneumoniae, Neisseria meningitidis, and
Haemophilus influenzae b).No detectable bacterial infection (NBI) (n = 97) Chil-
dren who presented with bacterial meningitis or bacter-
ial pneumonia, but who were negative for any bacteria
on culture, polysaccharide antigen test or PCR (S. pneu-
moniae, N. meningitidis, and H. influenzae b).Microbiological methods and malaria diagnosis
Blood, CSF and lung aspirate culture and PCR were per-
formed using standard microbiological techniques as
previously described [37,38] . Blood films were examined
by microscopy according to best standard practice of
district-hospital laboratories in Africa.
RNA extraction and quantification
Total RNA was extracted from whole blood using an opti-
mised method for the PAXgeneTM blood RNA kit (Qiagen,
West Sussex, UK), as previously described [28]. The RNA
was concentrated by precipitating overnight at −20°C with
2 μl linear acrylamide (5 mg/ml), (Ambion, Warrington,
UK), 0.5 volumes 7.5 M Ammonium acetate (Sigma, Dor-
set, UK) and 2.5 volumes ice cold 100% ethanol. The sam-
ples were centrifuged at 13,000 g, 4°C for 30 minutes. The
RNA pellet was washed twice with 0.5 ml ice cold 80%
ethanol, each time centrifuging at 4°C for 10 minutes at
13,000 g. The pellet was air dried for approximately 5 min-
utes and re-suspended in 11 μl of nuclease free water.
The total RNA concentration (ng/μl) and ratios (260/280
and 260/230) were measured using a NanoDrop ND-100
UV–vis spectrophotometer (Labtech International, Ring-
mer, UK) and the RNA integrity was assessed using the
Agilent 2100 Bioanalyser (Agilent Technologies, Edinburgh,
UK) pre- and post-concentration.
Reverse transcription for qPCR
RNA samples were DNAse treated (DNA Free, Ambion,
Warrington, UK] to remove any contaminating genomic
DNA. RNA (1 μg) was reverse transcribed with
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oligo (dT)12–18 (500 μg/ml) following the manufacturer’s
guidelines ((Invitrogen, Paisley,UK). The cDNA was
stored at −40°C until required.Real-time quantitative PCR measurement of target genes
The Human Universal Probe Library system (Roche,
Burgess Hill,UK) employing proprietary locked nucleic
acids (LNA) analogues was used for real-time quantita-
tive PCR (qPCR) to measure expression levels in genes
of interest. Using the Roche Online Assay Design
Centre, specific primers and an associated probe were
selected for the reference and target transcripts. Gene
expression was determined using real time qPCR on a
Roche LightCycler 480. Assays were designed using the
Roche Universal ProbeLibrary system. Table 4 shows the
primer sequences and the probe number for each assay.
Assays were run in triplicate 10 μl reactions in 384 well
plates. Each well contained 5 μl LightCycler 480 Probes
Master (2x concentration), 0.1 μl each primer (20 μM),
0.1 μl probe (10 μM), 0.7 μl water and 4 μl of cDNA
(1:40 dilution). The thermocycling conditions were: 95°C
for 5 minutes, then 50 cycles of 95°C for 10 seconds and
60°C for 30 seconds, a final cooling step of 40°C for 10
seconds completes the program. To compensate for var-
iations in cell number, RNA isolation, reverse transcrip-
tion and PCR amplification efficiency, 12 endogenous
transcripts (ACTB, B2M, GAPDH, GNB2L1, HMBS,
HPRT1, PGK-1, RPL13A, RPL32, SDHA, TBP and
YWHAZ) were screened and analysed using the GeN-
ORM algorithm [39], HPRT1, GAPDH and YWHAZ
were selected as suitable reference genes. A total of 176
randomly selected samples were analysed using qPCR.
The amounts of target genes expressed in a sample are
normalized to the average of the three endogenous con-
trols. This is given by ΔCT, where ΔCT is determined by
subtracting the average endogenous gene CT value from
the average target gene CT value. [CT target gene – CT
average (endogenous gene)]. The calculation of ΔΔCT
involves subtraction of ΔCT value for the controls from
the ΔCT value for the cases [ΔCT target gene(case) – ΔCT
target gene(control)]. 2
-ΔΔCt is the relative expression of
the target gene in cases compared to controls [28].NGAL, resistin and granulysin measurement by ELISA
NGAL (R&D Systems, Abingdon, UK), resistin (Uni-
versal Biologicals, Cambridge, UK) and granulysin
(ABO Swiss, Xiamen, China) were measured in
plasma samples using commercially available sandwich
enzyme immunoassays according to the manufac-
turers’ instructions. Assays were performed on plasma
samples if there was enough sample for the different
assays.Statistical analysis
Basic analysis was performed using SPSS for Windows,
version 15.0, (Illinois, USA), and ROCR and Hmisc
packages in R (http://www.r-project.org/) were used in
summarising the performances of biomarkers and com-
puting the net reclassification improvement (NRI). The
data, when plotted, did not follow a normal distribution,
and therefore the Mann Whitney Test was used to com-
pare distributions. Receiver operator characteristic
(ROC) curves were used to determine the areas under
the curve (AUCs) with 95% confidence intervals for the
biomarkers to predict SBI and death. The laboratory
assays for bacteriological confirmation and the markers
of infection were performed by investigators blinded to
the clinical data. The clinicians involved in managing
the cases were not involved in performing any of the la-
boratory assays.
Net reclassification improvement (NRI) [40] was used
to measure the additive value of measuring multiple bio-
markers and to quantify improvement in performance
over procalcitonin alone, which has previously been
shown to be the best biomarker of SBI in Malawian chil-
dren with signs of severe sepsis [29]. The magnitude of
NRI is more important than the statistical significance,
therefore we reported NRI with confidence intervals, as
well as significance values [40].
The study was reported according to STARD guide-
lines which includes method of recruitment of patients,
orders of test execution, and numbers of patients under-
going the tests under evaluation and the numbers of
patients with the reference standard [27] (Figure 1).
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